All In Biotech

Drug Trial Radar · NCT02141672

AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)

A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis

Last checked: Nov 19, 2026Latest source record: May 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 265 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

265

Actual

Start

Jun 2014

Primary completion

Jul 2016

Study completion Jan 2017

Sponsor

Lead sponsor
Aurinia Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
May 19, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the efficacy of 2 doses of voclosporin compared to placebo in achieving complete remission after 24 weeks of therapy in subjects with active lupus nephritis.

Conditions

  • Lupus Nephritis

Interventions

  • Voclosporin High DoseDrug

  • Voclosporin Low DoseDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects Achieving Complete Renal Remission at 24 WeeksTime frame: week 24

Locations

86 sites in 20 countries. Site status is shown where the registry gives one.

  • AURA-LV Site

    Los Angeles, California

  • AURA-LV Site

    Palo Alto, California

  • AURA-LV Site

    Gainesville, Florida

  • AURA-LV Site

    Miami, Florida

  • AURA-LV Site

    Farmington Hills, Michigan

  • AURA-LV Site

    Brooklyn, New York

  • AURA-LV Site

    New York, New York

  • AURA-LV Site

    Chapel Hill, North Carolina

  • AURA-LV Site

    Charlotte, North Carolina

  • AURA-LV Site

    Columbus, Ohio

  • AURA-LV Site

    Hershey, Pennsylvania

  • AURA-LV Site

    Chattanooga, Tennessee

  • AURA-LV Site

    Dallas, Texas

  • AURA-LV Site

    Houston, Texas

  • AURA-LV Site

    Dhaka, Bangladesh

  • AURA-LV Site

    Dhaka, Bangladesh

  • AURA-LV Site

    Minsk, Belarus

  • AURA-LV Site

    Minsk, Belarus

  • AURA-LV Site

    Minsk, Belarus

  • AURA-LV Site

    Vitebsk, Belarus

  • AURA-L Site

    Plovdiv, Bulgaria

  • AURA-LV Site

    Sofia, Bulgaria

  • AURA-LV Site

    Sofia, Bulgaria

  • AURA-LV Site

    Varna, Bulgaria

  • AURA-LV Site

    Hong Kong, China

  • AURA-LV Site

    Guayaquil, Ecuador

  • AURA-LV Site

    Quito, Ecuador

  • AURA-LV Site

    Tbilisi, Georgia

  • AURA-LV Site

    Tbilisi, Georgia

  • AURA-LV Site

    Guatemala City, Guatemala

  • AURA-LV Site

    Guadalajara, Mexico

  • AURA-LV Site

    Mexicali, Mexico

  • AURA-LV Site

    Oaxaca City, Mexico

  • AURA-LV Site

    Tlalpan, Mexico

  • AURA-LV Site

    Tlalpan, Mexico

  • AURA-LV Site

    Angeles City, Philippines

  • AURA-LV Site

    Batangas, Philippines

  • AURA-LV Site

    Cebu City, Philippines

  • AURA-LV Site

    Davao City, Philippines

  • AURA-LV Site

    Manila, Philippines

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.